SCHEMBL2191371

SCHEMBL2191371

Nc1ccc(O)nc1Nc1cc(Cl)c(Cl)cc1Cl

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 2/20 0.33
CYP3A4 P08684 2/20 0.32
THRB P10828 2/20 0.32
TSHR P16473 2/20 0.32
ALDH1A1 P00352 2/20 0.32
ALOX15 P16050 2/20 0.32
ESR2 Q92731 1/20 0.32
HPGD P15428 1/20 0.32
CASP1 P29466 1/20 0.32
RECQL P46063 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA12 O43570 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32
ATM Q13315 1/20 0.32
RET P07949 1/20 0.32
KIF5B P33176 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2193744 0.81 PDE5A (0.46) TSHRALDH1A1HSD17B10ATMNPC1
SCHEMBL2194055 0.79 LMNA (0.33) CYP3A4ALDH1A1CA1CA2CA12
SCHEMBL2192571 0.76 MAPT (0.50) CYP3A4ALDH1A1HPGDRAB9AGAA
SCHEMBL2193466 0.76 SYK (0.39) BRAFATM
SCHEMBL2192028 0.75 FGFR4 (0.42) TSHRALDH1A1CA1CA2NPC1
SCHEMBL2194873 0.73 CXCR2 (0.40) ALDH1A1KDRGAAHTT
SCHEMBL2192476 0.71 MAPT (0.44) ALDH1A1RECQLNPC1RAB9AHTT
SCHEMBL2196525 0.70 EPHX2 (0.48) CYP3A4TSHRALDH1A1ALOX15HPGD
SCHEMBL2191767 0.69 NUDT1 (0.47) CYP3A4ALDH1A1RECQLNPC1RAB9A
SCHEMBL2193574 0.69 KHK (0.39) BRAFALDH1A1ALOX15HSD17B10HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 BRAF 3139/4885CYP3A4 1147/4885THRB 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.